Literature DB >> 8627049

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.

S Sundar1, H W Murray.   

Abstract

Twenty-one Indian patients with visceral leishmaniasis who did not respond to or relapsed after 28-60 days of pentavalent antimony therapy were treated with amphotericin B lipid complex (ABLC). Five infusions (3 mg/kg each) given every second day over 9 days (total dose, 15 mg/kg) resulted in a 100% apparent cure response. In 4 other patients who had not responded to antimony, apparent cure was also induced by ABLC given 3 mg/kg a day 5 consecutive days (total dose, 15 mg/kg). Fever and chills developed routinely during the initial 2-h infusions; these reactions were tolerated and diminished with successive infusions. Six months after treatment, all 25 patients were healthy, had parasite-free bone marrow aspirates, and were considered cured. ABLC is effective short-course therapy for kala-azar patients who do not respond to conventional antimony treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627049     DOI: 10.1093/infdis/173.3.762

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Kala-azar--new developments in diagnosis and treatment.

Authors:  P Aggarwal; R Handa; S Singh; J P Wali
Journal:  Indian J Pediatr       Date:  1999 Jan-Feb       Impact factor: 1.967

Review 2.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters.

Authors:  Chiranjib Pal; Mousumi Raha; Anirban Basu; Keshab Chandra Roy; Anasuya Gupta; Monidipa Ghosh; Niranjan Prasad Sahu; Sukdeb Banerjee; Nirup Bikash Mandal; Santu Bandyopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

5.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.

Authors:  A B Mullen; K C Carter; A J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.

Authors:  Malika Larabi; Vanessa Yardley; Philippe M Loiseau; Martine Appel; Philippe Legrand; Annette Gulik; Christian Bories; Simon L Croft; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.

Authors:  C Petit; V Yardley; F Gaboriau; J Bolard; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

9.  Update in the treatment of cutaneous leishmaniasis.

Authors:  Sahar H Al-Natour
Journal:  J Family Community Med       Date:  2009-05

10.  Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.

Authors:  Jane E Dalton; Asher Maroof; Benjamin M J Owens; Priyanka Narang; Katherine Johnson; Najmeeyah Brown; Lovisa Rosenquist; Lynette Beattie; Mark Coles; Paul M Kaye
Journal:  J Clin Invest       Date:  2010-03-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.